Division of Alvogen Inc.
Latest From Alvogen Korea
Following the successful debut of Arena's Belviq in 2015, Orexigen's Contrave, which will be released in South Korea in the second quarter through its partner Kwang Dong Pharm, is set to boost the domestic obesity treatment market which had been depressed since the country banned sales of sibutramine-based drugs in 2010.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
LG Life Sciences ramps up its biosimilars development in Korea and Japan through deal with Japan’s Mochida that covers development and commercialization activities.
Predictions of heightened M&A activity among smaller South Korean generic drug firms gained firmer ground this week after an offhand comment by a government official pointed to interest by Teva in a mid-tier firm.
- Generic Drugs
- Therapeutic Areas
- Kunwha Pharmaceutical Co. Ltd.
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Alvogen Inc.
- Senior Management
- Lee Joo Hyung, EVP
- Contact Info
Phone: (82) 2-2047-7700
10, Gukjegeumyung-ro, Yeongdeungpo-gu
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.